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Background
Pembrolizumab (MK-3475), a humanized monoclonal
IgG4 antibody against programmed death receptor 1
(PD-1), is currently being studied in clinical trials across
more than 30 types of cancers. Immunotherapy with
anti–PD-1 monoclonal antibodies such as pembro-
lizumab shows robust, durable anti-tumor activity in
multiple indications including patients with advanced
melanoma. A more complete understanding of the
mechanism of action and biology associated with both
response and resistance to pembrolizumab is critical to
better inform on future clinical development and will
also provide insight into the development of additional
immuno-oncology therapies.
Methods and results
To further support the clinical development of pembroli-
zumab, muDX400 (an anti-PD1 murine surrorgate) was
tested in syngeneic mouse models. Response to muDX400
treatment in several syngeneic tumor models was broadly
classified into 3 categories: highly responsive, partially
responsive, and intrinsically resistant to therapy. Using a
multifaceted approach, tumors from these models were
extensively characterized at the molecular and cellular
level by gene expression profiling and whole exome
sequencing to help elucidate mechanisms of action and
biology associated with response and resistance to anti-
PD1 treatment.
These findings are also being compared to data that we
are obtaining from ongoing clinical trials with pembroli-
zumab to help better understand the translatability of
these preclinical models to the clinic. For example, both
the IFN-g and the expanded-immune signatures showed
statistically significant associations with ORR and PFS in
Keynote 001 Phase Ib melanoma trial. Analysis of top-
ranked genes on the platform led to the discovery of two
new signatures, “TCR-signaling” and “De novo” that were
enriched in T cell markers and MHC Class I and II
genes. Measuring immune-related biomarkers, including
T cell specific, antigen presentation–related, and IFN-g
signaling–related genes, may allow for improved selec-
tion of patients likely to respond to anti–PD-1 therapy
with pembrolizumab.
The translatability of molecular features such as gene
expression and mutation burden will be assessed in syn-
geneic mouse models.
Conclusions
These preclinical syngeneic tumor models allow us the
opportunity to formulate and test specific hypotheses to
more completely understand the biology behind the clini-
cal successes currently observed with the novel cancer
immunotherapies including anti-PD-1 antibodies such as
pembrolizumab.
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